# A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

> **NCT07532902** · PHASE1 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Diffuse Pleural Mesothelioma
- Gastroesophageal Carcinoma
- Urothelial Carcinoma

## Interventions

- **DRUG:** BMS-986504
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **DRUG:** 5-FU
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin
- **DRUG:** Gemcitabine
- **DRUG:** Platinum

## Key facts

- **NCT ID:** NCT07532902
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-07
- **Primary completion:** 2029-04
- **Final completion:** 2029-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07532902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07532902, "A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07532902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*